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1	  	  
Introduction	  
British	  employment	  scholars	  have	  long	  identified	  the	  existence	  of	  a	  skills	  problem	  in	  the	  UK.	  
The	   ‘matched	  plant’	   studies	   undertaken	  by	   the	  National	   Institute	   for	   Social	   and	   Economic	  
Research	   in	   the	   1980s	   and	   1990s	   identified	   how	   productivity	   levels	   in	   British	   firms	   were	  
significantly	   lower	   than	   in	   comparator	   firms	   in	   Europe,	   with	   the	   quality	   of	   products	  
manufactured	   also	   comparing	   unfavourably.	   A	   central	   finding	   was	   that	   these	   gaps	   and	  
weaknesses	  were	   attributable	   to	   the	   inferior	   intermediate	   and	   technical	   qualification	   and	  
skill	  profiles	  at	  the	  British	  firms	  (Daly	  et	  al	  1985;	  Steedman	  and	  Wagner	  1987,	  Mason	  et	  al	  
1994).	  	  
	  
A	   similar	   pattern	   of	   weak	   qualification	   and	   skills	   profiles	   alongside	   low	   quality	   good	   and	  
services	  was	   identified	   across	   the	   economy	   as	   a	  whole	   (Finegold	   and	   Soskice	   1988;	  Glynn	  
and	   Gospel	   1993;	   Keep	   and	  Mayhew	   1999).	   This	  was	   seen	   to	   be	   attributable	   to	   systemic	  
weaknesses,	  the	  mutual	   interaction	  of	  various	  problematic	  features	  of	  the	  British	  economy	  
including	   the	   short-­‐term	   investment	   horizons	   resulting	   from	   the	   nature	   of	   corporate	  
ownership	  patterns	  and	   financial	  market	  operation;	   the	  weakness	  of	  general	  management	  
skills;	  the	  flexible/lightly	  regulated	  nature	  of	  the	  labour	  market;	  and	  weak	  central	  employer	  
and	  trade	  union	  organisations	  and	  systems	  of	  worker	  representation	  (Finegold	  and	  Soskice	  
1988;	  Glynn	  and	  Gospel	  1993;	  Keep	  and	  Mayhew	  1999;	  Mayhew	  2013).	  	  
	  
It	   is	  now	  better	  recognised	  that	  the	  British	  economy	  possesses	  a	  number	  of	   internationally	  
competitive,	   quality	   focused	   and	   high-­‐skill	   sectors	   such	   as	   aerospace.	   However	   while	  
employment	   levels	   are	   at	   a	   record	   high,	   in	   general	   terms	   the	   UK	   economy	   continues	   to	  
suffer	   from	   serious	   weaknesses.	   The	   important	   manufacturing	   sector	   has	   witnessed	   a	  
dramatic	   decline;	   productivity	   levels	   continue	   to	   lag	   significantly	   behind	   countries	   such	   as	  
Germany	  and	  France;	  intermediate	  level	  skills	  are	  lacking;	  and	  there	  are	  serious	  problems	  of	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low	  pay,	  pay	  inequality	  and	  under	  employment	  (Lloyd	  and	  Mayhew	  2010;	  Wright	  2014;	  HM	  
Treasury	  2015;	  TUC	  2015).	  	  
	  
In	   addition	   to	   systemic	   weaknesses,	   the	   dominance	   of	   ‘laissez-­‐faire’	   principles	   and	  
consequent	   government	   reluctance	   to	   proactively	   shape	   the	   strategic	   performance	   and	  
direction	   of	   British	   industry	   has	   historically	   been	   identified	   as	   problematic	   (Finegold	   and	  
Soskice	  1988).	  While	  the	  UK	  government	  has	  become	  more	  hands-­‐on	  over	  time,	  policy	  has	  
been	  characterised	  by	  a	  dominant	  focus	  on	  measures	  aimed	  at	  improving	  the	  supply	  of	  skills	  
(Lloyd	  and	  Mayhew	  2010).	  It	  is	  argued	  that	  an	  active	  industrial	  policy	  comprising	  policies	  and	  
measures	  that	  support	  firms	  and	  sectors	  to	   innovate,	  compete	  on	  the	  basis	  of	  high	  quality	  
and	  become	  more	  productive;	  could	  more	  effectively	  underpin	  improvements	  in	  job	  quality	  
and	  skills	  utilization	  (Finegold	  and	  Soskice	  1988;	  Keep	  and	  Mayhew	  1999;	  Brown	  et	  al	  2015).	  	  
	  
However	  as	  Lloyd	  and	  Payne	   (2002:	  375-­‐6)	  note,	  while	  many	  authors	  have	  highlighted	   the	  
potential	  of	  an	  industrial	  policy	  to	  enable	  the	  UK	  to	  move	  to	  a	  higher	  skills	  path,	  with	  some	  
exceptions	  they	  have	  typically	  not	  elaborated	  in	  detail	  on	  what	  such	  a	  policy	  might	  look	  like	  
or	   how	   it	   would	   work.	   There	   is	   therefore	   a	   need	   for	   research	   of	   this	   nature.	   This	   is	  
accentuated	  by	  the	  fact	  that	  industrial	  policy	  has	  become	  more	  prominent	  as	  a	  result	  of	  the	  
financial	   crisis	   and	   recession,	   with	   national	   governments	   undertaking	   various	   efforts	   to	  
alleviate	  the	  crisis	  and	  promote	  growth	  via	  support	  for	  particular	  industries	  and	  regions	  (Clift	  
and	  Woll	  2012).	  Notably,	  there	  have	  been	  significant	  developments	  in	  this	  regard	  in	  the	  UK,	  
with	   the	   adoption	   of	   an	   active	   industrial	   strategy	   announced	   by	   the	   Conservative-­‐Liberal	  
coalition	   in	   2012	   centred	  on	   the	   development	   of	   close	   partnerships	  with	   strategic	   sectors	  
(BIS	  2012;	  Cable	  2012).	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This	   paper	   aims	   to	   contribute	   to	   academic	   understanding	   of	   the	   significance	   of	   industrial	  
policy	   for	   employment	   and	   skills,	   by	   examining	   the	   nature	   of	   UK	   government	   industrial	  
policy	  vis	  a	  vis	  the	  pharmaceutical	  sector	  and	  the	  performance	  and	  employment	  implications	  
of	   the	   same.	   In	   contrast	   to	   the	   general	   picture,	   pharmaceuticals	   has	  historically	   benefited	  
from	   significant	   government	   support,	   and	   examining	   developments	   in	   that	   sector	   may	  
therefore	  shed	  light	  on	  the	  employment	  consequences	  of	  an	  active	  industrial	  policy.	  	  
	  
The	   paper	   first	   outlines	   the	   economic	   and	   political	   dimensions	   and	   tangible	   forms	   of	  
industrial	  policy,	  before	  discussing	  its	  general	  impact	  on	  employment.	  Previous	  research	  on	  
industrial	   policy	   and	   employment	   is	   then	   considered.	   Next	   the	   research	   methods	   and	  
sectoral	  context	  are	  outlined,	  before	  the	  main	   findings	   from	  the	  UK	  pharmaceutical	  sector	  




Following	   Johhson	   (1984:8)	   we	   define	   industrial	   policy	   as	   involving	   ‘the	   initiation	   and	   co-­‐
ordination	   of	   governmental	   initiatives	   to	   leverage	   upward	   the	   productivity	   and	  
competitiveness	  of	  the	  whole	  economy	  and	  of	  particular	  industries	  in	  it.’	  Economists	  outline	  
how	   industrial	   policy	   may	   be	   ‘horizontal’	   or	   ‘selective’	   (also	   labeled	   ‘vertical’)	   in	   nature	  
(Chang	  1994;	  Crafts	  2012;	  Mayhew	  2013).	  Horizontal	  policies	  apply	  across	  all	  organizations,	  
for	   example	   tax	   incentives	   or	   regulatory	   requirements.	   Selective	   policies	   are	   applied	   to	  
particular	  industries	  or	  firms,	  for	  example	  state	  investment	  in	  renewable	  energy.	  	  
	  
A	   primary	  motivation	   for	   the	   introduction	   of	   industrial	   policies	   commonly	   outlined	   in	   the	  
literature	   is	   to	   correct	   market	   failures	   (Chang	   1994;	   Crafts	   2012;	   Mayhew	   2013).	   For	  
example	  governments	  may	  invest	  in	  particular	  technologies	  or	  industries	  that	  will	  generate	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revenue	  in	  the	  long	  term	  where	  capital	  markets	  refuse	  to	  do	  so	  given	  the	  lengthy	  timeframe	  
before	  revenue	  generation.	  A	  second	  important	  rationale	  for	  industrial	  policy	  measures	  is	  to	  
reap	  the	  benefits	  arising	  from	  ‘positive	  externalities.’	  	  An	  example	  here	  is	  incentivizing	  firm-­‐
level	   investment	   in	   R&D:	   this	   generates	   benefits	   for	   the	   wider	   economy	   beyond	   the	  
individual	  firm	  and	  hence	  it	  is	  in	  the	  public	  interest	  to	  promote	  it.	  	  
	  
The	   emergence	   of	   ‘new	   institutionalist’	   and	   technology	   centred	   theories	   of	   economic	  
growth	   has	   led	   to	   an	   increasing	   acceptance	   of	   the	   role	   of	   industrial	   policy	   over	   recent	  
decades	  (Chang	  1994).	  These	  emphasise	  how	  public	  institutions	  and	  regulation	  support	  the	  
development	  and	  functioning	  of	  markets,	  with	  state	  investment	  in	  new	  technology	  essential	  
in	   overcoming	   the	   market	   failures	   highlighted	   above	   (Chang	   1994;	   Rodrik	   2008).	  
Developments	   in	  the	  related	  fields	  of	   innovation	  studies	  and	  economic	  geography	  similarly	  
emphasise	   the	   value	   of	   industrial	   policy	   in	   the	   contemporary	   economy,	   highlighting	   the	  
importance	   of	   state	   investment	   in	   research	   and	   other	   ‘factor	   conditions’	   as	   well	   as	   the	  
centrality	  of	   clusters	   and	  networks	  underpinned	  by	  public	   institutions	   (Cooke	  and	  Morgan	  
1998;	  Etzkowitz	  and	  Leydesdorff	  2000;	  Lundvall	  2007).	  	  
	  
Measures	  and	  Instruments	  
Historically	   it	   was	   common	   for	   governments	   to	   intervene	   directly	   in	   product	  markets,	   for	  
example	   by	   restricting	   imports	   of	   particular	   products	   to	   support	   indigenous	   firms	   or	  
establishing	   state	   monopolies	   in	   certain	   activities.	   However	   globalisation,	   the	   growing	  
importance	  of	  knowledge-­‐based	  activity	   for	  economic	  development,	  and	  multilateral	   trade	  
agreements	  emerging	  from	  the	  World	  Trade	  Organisation,	  have	  led	  to	  significant	  change	  in	  
the	  general	  orientation	  of	  industrial	  policy	  and	  the	  particular	  instruments	  and	  tools	  utilised	  
by	  policymakers	  over	  recent	  decades	  (Bianchi	  and	  Labory	  2006;	  Weiss	  2010).	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Table	  1	  below	  outlines	   ten	  key	  general	   industrial	  policy	  activities	   together	  with	  associated	  
examples	   of	  what	   these	   involve	   identified	   from	   the	   industrial	   policy	   literature	   (e.g.	   Porter	  
1990;	  Bianchi	  and	  Labory	  2006;	  Huggins	  and	  Izushi	  2007;	  Bloch	  2008;	  Weiss	  2010).	  
	  
	   <<	  insert	  table	  1	  about	  here>>	  
	  
While	  deregulation	  and	  the	  enhancement	  of	  product	  market	  competition	  are	  included	  in	  the	  
table,	   the	   other	   more	   positive	   and	   proactive	   measures	   outlined	   are	   necessary	   to	   move	  
economies	  into	  higher	  value	  market	  niches	  (Porter	  and	  Ketels	  2003).	  Alongside	  the	  existence	  
of	   pertinent	  measures,	   the	   literature	   highlights	   how	   the	   state’s	  management	   of	   industrial	  
policy	  is	  important,	  with	  the	  need	  for	  governments	  to	  ensure	  coherence	  between	  measures,	  
policies	   and	   decision-­‐making	   levels	   as	   well	   as	   to	   continually	   adapt	   and	   refine	   policies	  
emphasised	  (Bianchi	  and	  Labory	  2006;	  Huggins	  and	  Izushi	  2007).	  	  
	  
The	  Political	  and	  Contested	  Nature	  of	  Industrial	  Policy	  	  
Historically	  there	  has	  been	  fundamental	  disagreement	  among	  academics,	  policymakers	  and	  
politicians	  regarding	  the	  role	  and	  effectiveness	  of	   industrial	  policy.	  Those	  with	  a	  neoliberal	  
perspective	   have	   taken	   the	   view	   that	   industrial	   policy	   is	   fundamentally	   ineffective,	   that	  
governments	  are	  not	   capable	  of	   successfully	  directing	  and	  allocating	   resources	   to	   industry	  
and	  may	  be	  subject	   to	   ‘capture’	  by	  particular	   interest	  groups.	  This	  perspective	  argues	   that	  
government’s	   primary	   role	   is	   to	   ensure	   the	   free	   operation	   of	   markets	   and	   conditions	  
enabling	  private	  enterprise	  and	  individual	  initiative	  to	  flourish	  (Chang	  1994;	  Weiss	  2010).	  
	  
In	  contrast,	  those	  favouring	  social	  democratic	  perspectives	  and	  emphasising	  the	  importance	  
of	  institutions	  and	  agency,	  have	  argued	  that	  the	  state	  has	  a	  central	  role	  to	  play	  in	  directing	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economic	  activity	  and	  promoting	  growth	  and	  development,	  and	  that	  it	  is	  capable	  of	  doing	  so	  
(Rueschemeyer	  and	  Evans	  1985;	  Chang	  1994;	  Weiss	  2010).	  	  	  
	  
The	   political	   and	   contested	   nature	   of	   industrial	   policy	   has	   been	   very	   apparent	   in	   the	   UK.	  
While	  during	   the	  50s,	  60s	  and	  70s	   there	  was	   some	  significant	   support	   for	  active	   industrial	  
policies,	  the	  election	  of	  the	  Thatcher	  led	  Conservative	  government	  in	  1979	  led	  to	  a	  decisive	  
shift	   to	   a	   predominantly	   neo-­‐liberal	   approach,	   centred	   on	   ideological	   commitment	   to	   the	  
free	  operation	  of	  market	  forces.	  This	  led	  to	  a	  marked	  reduction	  in	  industrial	  policy	  initiatives	  
and	  expenditure	  (Grant	  1982;	  Coates	  2000).	  As	  noted	  above,	  critics	  have	  identified	  this	  shift	  
in	  government	  policy	  as	  contributing	  to	  serious	  weakness	   in	   industrial	  and	  wider	  economic	  
performance	  in	  the	  UK,	  consequently	  negatively	  impacting	  both	  the	  quality	  and	  quantity	  of	  
employment.	   They	   have	   called	   for	   the	   adoption	   of	   an	   active	   industrial	   policy	   to	   address	  
these	   weaknesses	   (Finegold	   and	   Soskice	   1988;	   Delbridge	   and	   Lowe	   1998;	   Coffey	   and	  
Thornley	  2009).	  	  	  	  	  
	  
Industrial	  Policy	  and	  Employment	  	  
Establishing	   the	   impact	   of	   industrial	   policy	  measures	   given	   the	   presence	   of	   various	   other	  
parallel	  influences	  is	  challenging	  and	  the	  subject	  of	  much	  debate	  (Greene,	  Mole	  and	  Storey	  
2008).	  Whilst	   acknowledging	   this,	   it	   is	   evident	   that	   industrial	   policy	   can,	   at	   a	   fundamental	  
level,	  greatly	  influence	  business	  creation,	  survival	  and	  success;	  with	  important	  consequences	  
for	  employment,	  work	  organization	  and	  skills	  within	  particular	  companies	  or	  sectors	  (Stiglitz	  
and	  Lin	  2013).	  Industrial	  policy	  can,	  via	  its	  influence	  on	  firm	  strategies	  and	  performance,	  be	  
seen	  as	  a	  ‘first	  order’	  determinant	  of	  employment	  and	  skills	  outcomes	  (Purcell	  1989).	  	  
	  
Related	  interventions	  may	  affect	  the	  quantity	  and	  quality	  of	  employment,	  with	  the	  creation	  
of	  high-­‐wage,	  high-­‐skill	  jobs	  typically	  a	  primary	  objective	  (Warwick	  2013).	  Selective	  industrial	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policy	   interventions	  may	  be	   ‘defensive/reactive’	  or	   ‘strategic’	   in	  nature.	  The	  former	  aim	  to	  
protect	   or	   upgrade	   existing	   activities	   and	   jobs.	   In	   contrast,	   the	   latter	   are	   focused	   on	   the	  
development	  of	  new	  activities	  or	  capabilities,	  resulting	  in	  the	  creation	  of	  new	  jobs	  (Warwick	  
2013:	  29).	  	  
	  
British	  skills	  researchers	  have	  examined	  the	  economic	  and	  industrial	  policies	  adopted	  by	  the	  
‘East	  Asian	  Tiger’	  economies	  Singapore,	  South	  Korea	  and	  Taiwan	   (Green	  et	  al	  1999;	  Green	  
and	   Sakamoto	   2001).	   This	   research,	   drawing	   on	   interviews	   with	   policymakers,	   employers	  
and	   expert	   observers	   in	   addition	   to	   secondary	   data,	   highlights	   how	   the	   governments	   of	  
these	  countries	  have	  taken	   interventionist	  and	  closely	  coordinated	  measures	  over	  decades	  
to	  promote	  economic	  development.	   This	  has	   involved	   targeting	  and	   support	   for	  particular	  
activities	   or	   industries;	   high	   levels	   of	   public	   investment	   in	   infrastructure,	   manufacturing	  
capacity	   and	   R	  &	  D;	   the	   introduction	   of	   financial	   incentives	   for	   foreign	   direct	   investment;	  
legal	   instruments	  mandating	   staff	   training;	   and	   the	   systematic	  matching	  of	   skills	   supply	   to	  
industry	  demand.	  This	  has	  underpinned	  strong	  growth	  and	  a	  progressive	  transition	  to	  higher	  
value	   activities	   in	   these	   countries,	   as	   well	   as	   dramatic	   increases	   in	   qualification	   and	   skill	  
levels	  over	  time	  (Green	  et	  al	  1999;	  Green	  and	  Sakamoto	  2001).	  
	  
Hannon	  et	  al	  (2011)	  outline	  how	  active	  industrial	  policy	  has	  been	  similarly	  central	  to	  the	  Irish	  
pharmaceutical	   sector’s	   strong	   growth	   and	   the	   creation	   of	   a	   large	   number	   of	   high-­‐wage,	  
high-­‐skill	  jobs	  there.	  Qualitative	  case	  studies	  highlight	  how	  individual	  firms	  have	  undertaken	  
new	  investments	  in	  higher	  value,	  knowledge-­‐intensive	  activities	  such	  as	  biopharmaceuticals,	  
in	   response	   to	   strategic	   initiatives	   on	   the	   part	   of	   the	   Irish	   government	   and	   associated	  
support	  measures	   relating	   to	   finance,	   R	   &	   D,	   skills	   and	   training.	   These	   have	   underpinned	  




This	   paper	   examines	   the	   nature	   of	  UK	   government	   industrial	   policy	   in	   the	   pharmaceutical	  
sector	  and	   the	  employment	   implications	  of	   the	   same.	  We	  draw	  on	  eleven	   interviews	  with	  
policy	   makers	   and	   industry	   officials	   conducted	   in	   2008-­‐09.	   	   These	   were	   used	   to	   obtain	  
information	  on	  the	  various	  policies	  and	  programmes	  of	  relevance	  to	  the	  sector	  adopted	  by	  
government	   and	   public	   agencies,	   and	   industry	   officials’	   views	   regarding	   their	   impact	   and	  
effectiveness.	  	  	  
	  
In	   addition,	   seventy	   two	   interviews	   were	   conducted	   at	   five	   pharmaceutical	   companies	  
during	  2009,	  comprising	  four	  multinationals	  and	  one	  small	  university	  spin-­‐out	  (see	  table	  2).	  
Interviews	  lasting	  between	  45	  minutes	  and	  an	  hour	  were	  undertaken	  with	  general,	  HR	  and	  
training	   managers	   as	   well	   as	   line	   managers,	   scientists	   and	   other	   operational	   staff.	  
Management	   interviews	   identified	  the	  nature	  of	   firm	  strategies	  and	  the	  extent	  and	   impact	  
of	  external	  interactions	  and	  the	  wider	  policy	  context.	  Interviewees	  with	  scientists	  and	  other	  
operational	  staff	  addressed	  perceptions	  of	   job	  satisfaction	  and	  views	  about	  working	   in	   the	  
British	  sector.	  Interviews	  were	  recorded	  and	  transcribed	  where	  possible.	  
	  
While	  the	  views	  and	  perceptions	  of	  operational	  staff	  are	  of	  great	  importance	  (Hannon	  et	  al	  
2011),	   due	   to	   space	   restrictions	  here	  we	   focus	  on	  data	   from	   the	  management	   interviews.	  
These	  are	  supplemented	  by	  secondary	  data	  on	  relevant	  themes	  including	  previous	  academic	  
research;	   official	   statistics;	   government,	   state	   agency	   and	   industry	   body	   documents	   and	  
reports;	  periodicals	  and	  other	  news	  sources.	  	  
	  
In	   examining	   the	   employment	   effects	   of	   industrial	   policy	  we	   focus	   on	   three	   key	   objective	  
aspects:	   trends	   in	   numbers	   employed,	   wage	   levels	   and	   skill	   levels	   (as	   measured	   by	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qualification	  profiles).	  Additional	   industry	  performance	  data	   is	   included	  to	  enable	  a	  holistic	  
assessment	  of	  trends	  in	  the	  sector.	  	  	  	  
	  
	   <<	  insert	  table	  2	  about	  here>>	  
	  
The	  pharmaceutical	  sector	  
Pharmaceuticals	  is	  frequently	  identified	  as	  an	  important	  ‘knowledge	  economy’	  sector,	  being	  
characterised	   by	   high	   relative	  wage	   and	   skill	   levels	   (e.g.	   Brinkley	   2008).	   It	   has	   historically	  
focused	  on	  the	  development	  of	  ‘small	  molecule’	  chemical	  compounds	  that	  affect	  particular	  
targets	  or	  processes	  in	  the	  human	  body	  (van	  Egeraat	  and	  Barry	  2008).	  Product	  development	  
in	   the	  sector	   is	  distinctive	   for	   its	   lengthy,	  complex	  and	  costly	  nature	  and	  has	  consequently	  
been	   dominated	   by	   large	   multinationals	   from	   the	   US,	   Western	   Europe	   and	   Japan	  
(Achilladelis	  and	  Antonakis	  2001).	  	  
	  
Since	   the	   1980s	   pharmaceutical	   companies	   have	   come	   under	   strong	   competitive	   and	  
operational	   pressure	   due	   to	   a	   decline	   in	   the	   rate	   of	   successful	   new	   drug	   development;	  
shorter	  effective	  patent	  life	  due	  to	  lengthier	  development	  and	  approval	  processes;	  increased	  
competition	   from	   manufacturers	   of	   generic	   drugs;	   and	   downward	   pressure	   on	   margins	  
exerted	   by	   cost-­‐conscious	   national	   governments	   (Froud	   et	   al.	   1998).	   The	   progressive	  
development	  of	  the	  medical	  biotechnology	  or	  biopharmaceutical	  sector	  has	  also	  challenged	  
existing	   firms	   and	   operating	   models.	   The	   latter	   is	   centred	   on	   the	   use	   of	   large	   molecules	  
derived	   from	   living	   organisms	   as	   active	   ingredients	   instead	   of	   chemically	   based	   small	  
molecules,	  with	  SMEs	  at	  the	  forefront	  of	  innovation	  (Ernst	  and	  Young	  2010).	  	  
	  
These	  trends	  and	  pressures	  have	  prompted	  very	  significant	  rationalization	  within	  the	  world	  
industry,	   involving	   various	   acquisitions	   and	  mergers	   between	   firms	   as	  well	   as	   cost-­‐cutting	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within	   individual	   businesses	   (Froud	   et	   al.	   1998).	   A	   prominent,	   related	   trend	   in	   the	   last	  
decade	   has	   been	   the	   enormous	   growth	   in	   outsourcing	   of	   activities	   such	   as	   molecule	  
screening	  or	   later	   stage	  clinical	   research.	  There	   is	  also	  a	  move	  among	   the	   leading	   firms	   to	  
target	   investments	   in	  fundamental	  research	  to	  emerging	  countries	  such	  as	  China	  and	  India	  
who	  are	  producing	  large	  numbers	  of	  science	  graduates	  (Ernst	  and	  Young	  2010).	  	  
	  
Industrial	  Policy	  and	  the	  UK	  Pharmaceutical	  sector	  
Various	   aspects	   of	   the	   national	   policy	   and	   institutional	   context	   historically	   promoted	   the	  
development	   of	   the	   UK	   pharmaceutical	   sector,	   including	   the	   favourable	   rules	   of	   the	   UK’s	  
pricing	   system	   for	   pharmaceutical	   products;	   a	   responsive	   product	   safety	   regime	   involving	  
strong	   industry	   input	   alongside	   academic	   expertise;	   the	   expansion	   of	   the	   National	   Health	  
Service;	  very	  strong	  public	  science	  base;	  and	  the	  government’s	  strategic	  attraction	  of	  foreign	  
direct	   investment	   of	   an	   innovative	   nature	   (Hancher	   1990;	   Thomas	   1994;	   Abraham	   2009;	  
Owen	  2010).	  Concern	  on	  the	  part	  of	  government	  to	  assist	  the	  industry	  and	  deference	  to	  its	  
interests	  and	  demands	  have	  frequently	  been	  evident	  (Hancher	  1990;	  Abraham	  2009).	  	  	  
	  
Over	  the	  last	  10-­‐15	  years	  state	  industrial	  policy	  towards	  the	  sector	  has	  become	  progressively	  
more	   explicit	   and	   active.	   The	   Labour	   government	   established	   the	   Pharmaceutical	   Industry	  
Competitive	   Taskforce	   in	   2000	   to	   examine	   the	   competitive	  position	  of	   the	   industry	   (PICTF	  
2001).	  This	  led	  to	  the	  establishment	  of	  the	  Ministerial	  Industry	  Strategy	  Group,	  which	  meets	  
twice	   a	   year	   bringing	   together	   industry	   and	   government	   representatives	   to	   discuss	   key	  
issues	  affecting	  the	  sector.	  	  
	  
The	   industry	   benefited	   from	   the	   substantial	   increase	   in	   government	   science	   funding	   from	  
2004	  and	  the	  concerted	  drive	  to	  ensure	  that	  research	  councils	  such	  as	  the	  Medical	  Research	  
Council	   collaborated	  more	   closely	  with	   industry	   and	   undertake	   research	   of	   benefit	   to	   the	  
11	  	  
latter	   (interviews).	   In	   2009	   the	   government	   set	   up	   the	   Office	   for	   Life	   Sciences	   as	   a	   cross	  
departmental	  body	  with	   the	  task	  of	  promoting	  the	  competitiveness	  of	   the	  UK	   life	  sciences	  
sector.	  Various	  working	  groups	  comprising	   representatives	   from	  government,	   industry	  and	  
academia	   were	   formed,	   which	   led	   to	   the	   development	   of	   an	   overarching	   ‘blueprint’	  
document	  in	  2009	  and	  subsequent	  progress	  report	  in	  2010	  (OLS	  2010).	  	  
	  
The	  policies	  of	  the	  Conservative-­‐Liberal	  government	  2010-­‐2015	  built	  closely	  on	  those	  of	   its	  
predecessor.	  An	  express	  policy	  of	  protecting	  the	  science	  budget	  was	  adopted.	  A	  Strategy	  for	  
UK	   Life	   Sciences	  was	   set	   out	   in	  December	   2011,	  which	  outlined	   the	  objective	   that	   the	  UK	  
would	   ‘become	   the	   global	   hub	   for	   life	   sciences’	   (BIS/OLS	  2011:	   6).	   The	   strategy	   contained	  
thirty-­‐one	   specific	   actions	   to	   be	   implemented,	   with	   progress	   and	   additional	   initiatives	  
outlined	   in	   a	   report	   published	   in	   December	   2012	   (HM	   Government	   2012).	   A	   dedicated	  
Minister	   for	   Life	   Sciences	   was	   appointed	   in	   2014	   with	   further	   significant	   investment	  
initiatives	  announced	  (HM	  Treasury/BIS	  2014).	  Whilst	  reportedly	  reviewing	  and	  questioning	  
the	   general	   merits	   of	   industrial	   policy	   (Financial	   Times,	   June	   8th	   2015),	   the	   Conservative	  
government	   elected	   in	   May	   2015	   has	   continued	   to	   provide	   dedicated	   support	   to	  
pharmaceuticals.	  Table	  3	  summarises	  key	  initiatives	  resulting	  from	  the	  OLS,	  Strategy	  for	  Life	  
Sciences	  and	  subsequent	  policy	  development	  aimed	  at	  strengthening	  the	  sector.	  	  
	  
<<insert	  table	  3	  about	  here>>	  
	  
The	   table	   outlines	   a	   large	   number	   of	   significant	   initiatives	   in	   support	   of	   the	   UK	  
pharmaceutical	   industry,	   comparable	   in	  nature	  and	   in	   some	  ways	  more	   resource	   intensive	  
than	  in	  comparator	  countries	  such	  as	  France	  (BMI	  2015;	  HM	  Government	  2015b).	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The	  perceived	  importance	  of	  the	  sector	  and	  related	  employment	  came	  sharply	  to	  the	  fore	  in	  
Spring	   2014	   when	   the	   US	   multinational	   Pfizer	   attempted	   to	   acquire	   the	   British	   firm	  
AstraZeneca.	   The	   attempted	   takeover,	   which	   was	   ultimately	   unsuccessful,	   was	   met	   with	  
outrage	  and	  scepticism	  on	  the	  part	  of	  politicians	  and	  industry	  figures	  due	  to	  fears	  about	  its	  
implications	  for	  jobs	  and	  the	  wider	  position	  of	  UK	  science	  (House	  of	  Commons	  2014).	  
	  
Next	  we	  consider	  the	  impact	  of	  these	  measures	  and	  the	  broader	  industrial	  policy	  context	  for	  
performance	  and	  employment	  in	  the	  sector,	  drawing	  on	  the	  policy	  related	  interviews	  and	  in	  
particular	  the	  case	  studies	  of	  the	  five	  firms.	  	  Key	  issues	  and	  themes	  identified	  are	  addressed	  
in	  turn.	  	  	  	  
	  
The	  institutional	  and	  policy	  contexts,	  firm	  strategies	  and	  innovation	  	  
Access	  to	  skills	  
For	   the	   large	   firms	   P1,	   P2,	   P3	   and	   P4,	   the	   ability	   to	   recruit	   large	   numbers	   of	   high	   quality	  
graduates	   and	   research	   scientists	   from	   pharmaceutical	   or	   medical	   related	   disciplines	   had	  
historically	   been	   a	   key	   strength	   of	   the	   British	   context,	   with	   managers	   highlighting	   the	  
enormous	  capabilities	  and	  expertise	  of	  their	  staff.	  This	  situation	  had	  changed	  however	  and	  
in	  the	  words	  of	  a	  senior	  manager	  at	  P1	  was	  now	  “more	  on	  a	  knife-­‐edge.”	  	  
	  
These	   firms	   reported	   skill	   shortages	   in	   important	   traditional	   areas	   such	   as	   clinical	  
pharmacology,	  toxicology	  and	   in	  vivo	  sciences,	  as	  well	  as	  newer	  areas	  such	  as	  biochemistry	  
and	   computational	   statistics.	   Interviewees	   noted	   how	   the	   school	   curriculum	   meant	   that	  
graduates	   frequently	   lacked	   adequate	   mathematical	   skills,	   while	   many	   university	   science	  
qualifications	  did	  not	  provide	  graduates	  with	  essential	   knowledge	  and	  practical	   training	   in	  
key	  disciplinary	  subjects.	  A	  senior	  manager	  at	  P5	  made	  similar	  observations	  and	  noted	  how	  
he	  was	  having	  great	  difficultly	  recruiting	  a	  laboratory	  technician	  who	  could	  do	  in-­‐vivo	  work.	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In	  order	  to	  address	  these	  gaps,	  the	  large	  firms	  were	  in	  close	  contact	  with	  government	  both	  
directly	   and	   via	   the	   Association	   of	   British	   Pharmaceutical	   Industries	   (ABPI).	   While	  
interviewees	  spoke	  positively	  of	   interaction	  with	  government	  about	  the	  school	  curriculum,	  
they	  were	  more	  critical	  about	  developments	   in	  higher	  education.	  While	  HEFCE,	   the	  Higher	  
Education	   Funding	   Council	   for	   England,	   had	   provided	   additional	   funding	   enabling	   more	  
students	  to	  be	  recruited	  onto	  chemistry	  and	  physics	  degrees,	  support	  for	  bioscience	  courses	  
was	   lacking	   (ABPI	   2008).	   The	   funding	   of	   laboratory	   based	   disciplines	   was	   seen	   to	   be	  
inadequate	  and	   there	  was	  a	  perceived	  need	   for	   stronger	  efforts	  on	   the	  part	  of	  HEFCE	  and	  
the	  university	  sector	  to	  address	  the	  industry’s	  skills	  requirements	  (ABPI	  2008).	  	  	  
	  
P1,	   P3	   and	   P4	   did	   obtain	   some	   funding	   from	   higher	   education	   authorities	   and	   research	  
councils	   to	   provide	   dedicated	   resources	   for	   the	   development	   of	   in-­‐vivo	   skills	   at	   four	  
universities.	   A	   senior	   manager	   noted	   at	   P3	   how	   this	   had	   been	   an	   example	   of	   proactive	  
‘industrial	   activism’	  on	   the	  part	  of	   the	   firms,	  but	   lamented	   the	   small	   amount	  of	   resources	  
involved	   (£12	   million).	   	   In	   July	   2014,	   the	   government	   awarded	   £32	   million	   for	   the	  
establishment	  of	  an	  employer-­‐led	  ‘Science	  Industry	  Partnership’	  with	  the	  purpose	  of	  helping	  
science	  employers	  address	  skills	  gaps.	  This	  dedicated	  skills	  organization,	  in	  which	  life	  science	  
companies	  play	  a	  central	  role,	  has	  subsequently	  set	  up	  an	  industry	  degree	  scheme	  focusing	  
on	   employability	   and	   Masters	   in	   Formulation	   Science	   and	   Technology,	   among	   other	  
initiatives.	  	  	  
	  
The	  multinational	   status	   of	   the	   large	   firms	  was	   pertinent	   in	   relation	   to	   skills.	  Much	   lower	  
level	   R&D	   activities	   such	   as	   molecule	   screening	   had	   long	   been	   moved	   to	   lower	   cost	  
international	   locations.	   There	  was	  also	  evidence	  of	   a	   trend	   towards	   the	   transfer	  of	  higher	  
value	   activities.	   P3	   had	   for	   example	   recently	   opened	   an	   R&D	   centre	   in	   China,	   where	  
according	  to	  a	  senior	  recruitment	  manager	  there	  was	  a	  ‘great	  skills	  set.’	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Access	  to	  Knowledge	  and	  Research	  Collaborations	  
Each	  of	  the	  large	  firms	  P1,	  P2,	  P3	  and	  P4	  had	  close	  research	  links	  with	  UK	  universities,	  with	  
strong	   relationships	   also	  with	   clinical	   organisations,	   research	   councils	   and	   health	   research	  
charities.	  This	   involved	  contact	  with	   individual	   researchers	  at	  particular	   institutions	  as	  well	  
as	   larger	   collaborative	   projects	   involving	   other	   firms	   and	   organisations.	   The	   small	   firm	   P5	  
was	   itself	   a	   university	   spin-­‐out	   and	   had	   very	   close	   links	  with	   a	   number	   of	   UK	   universities	  
regarding	  product	  development.	  
	  
The	  extent	  of	  external	  interactions	  undertaken	  by	  P3	  was	  striking.	  The	  following	  quote	  from	  
a	  senior	  manager	  gives	  a	  sense	  of	  this:	  	  
	  
If	   you	   name	   a	   university	   I’ll	   tell	   you	  what	  we’ve	   got	   there.	   There	   are	   lots	   of	   links	  
throughout	  the	  whole	  company	  in	  various	  guises……each	  of	  our	  R	  &	  D	  business	  units	  
have	  strategic	  plans	  and	  within	  that	  there	  will	  be	  an	  external	  component	  that’s	  been	  
up	  front	  and	  thought	  about.	  
	  
The	   manager	   explained	   that	   the	   company’s	   objective	   of	   increasing	   its	   throughput	   of	  
chemical	  entities	  was	  necessitating	  an	  expansion	  in	  external	  contacts	  and	  collaborations.	  In	  
this	  regard,	  P3	  had	  recently	  signed	  an	  extensive	  collaboration	  agreement	  with	  a	  large	  health	  
charity	   involving	   the	   sharing	  of	   research	   targets.	  P4	  engaged	   in	  comparable	   collaborations	  
and	   had	   a	   similarly	   large	   number	   of	   external	   contacts	   with	   UK	   universities	   and	   research	  
institutions.	  
	  
While	  noting	  that	  expertise	  in	  particular	  areas	  was	  narrowly	  distributed,	  interviewees	  at	  all	  
five	  firms	  highlighted	  the	  strength	  of	  the	  pharmaceutical	  and	  medical	  related	  research	  being	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undertaken	   in	   the	  UK	  and	  noted	  how	  this	   constituted	  a	   significant	   resource	  and	  source	  of	  
competitive	  advantage.	  A	  policy	  manager	  at	  P2	  explained	  how	  that	  company’s	  UK	  research	  
site	  had	  been	  chosen	  as	  the	  location	  for	  a	  strategic	  new	  investment	  in	  the	  neuroscience	  area	  
due	   to	   the	   strength	   of	   UK	   research.	   P1,	   P3	   and	   P4	  were	   involved	   in	   a	   large	   collaborative	  
project	  with	  a	  British	  university.	  A	  senior	  manager	  at	  P3	  described	  the	  particular	  knowledge	  
base	   there	   as	   ‘second	   to	  none	   in	   the	  world’,	   and	  explained	  how	   that	   company	  undertook	  
various	  projects	  with	  the	  university	  that	  were	  of	  substantial	  strategic	  benefit.	  	  
	  
Support	  for	  Innovation	  in	  the	  Market	  Place	  
The	   lack	  of	   investment	   finance	   in	   the	  UK	   sector	  was	   identified	   as	   problematic	   by	   industry	  
officials	  as	  well	  as	  by	  a	  senior	  manager	  at	  P5	  the	  recent	  start-­‐up.	  This	  was	  seen	  to	  place	  a	  
substantial	  constraint	  on	  the	  translation	  of	  discoveries	  into	  marketable	  products	  and	  hence	  
the	   development	   of	   the	   biomedical/biopharma	   sector.	   While	   there	   has	   been	   a	   recent	  
notable	  improvement,	  the	  UK	  continues	  to	  lag	  far	  behind	  the	  US	  in	  this	  regard	  (BIA	  2015).	  	  	  	  	  	  
	  
The	  case	  study	  firms	  had	  regular	  contact	  with	  the	  Technology	  Strategy	  Board	  (now	  Innovate	  
UK),	  the	  state	  agency	  with	  the	  role	  of	  promoting	  business	  innovation.	  The	  MNCs	  P1	  and	  P3	  
and	   small	   firm	   P5	   had	   all	   recently	   received	   substantial	   funding	   from	   the	   TSB	   under	   its	  
collaborative	   research	   competition	   programme	   alongside	   other	   firms	   and	   research	  
institutions.	   Awards	   for	   individual	   projects	   were	   over	   a	   million	   pounds	   and	   supported	  
product	  or	  process	  development.	  For	  P1	  and	  P3	  these	  awards	  were	  seen	  to	  be	  valuable,	  with	  
the	   fact	   that	   they	   enabled	   additional	   funding	   to	   be	   leveraged	   from	  other	   parties	   involved	  
being	  particularly	  useful.	  
	  
For	   P5	   funding	   from	   the	   TSB	   had	   been	   crucial	   to	   the	   survival	   of	   the	   business	   against	   the	  
context	  of	   the	  serious	   lack	  of	   investment	   finance.	  According	   to	  a	   senior	  manager,	   recently	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winning	  a	  TSB	  grant	  had	  been	  an	  ‘absolute	  lifeline’,	  which	  allowed	  the	  company’s	  research	  
programme	  to	  be	  progressed	  more	  quickly.	  In	  addition,	  on	  the	  strength	  of	  the	  TSB	  award	  the	  
company	   had	   been	   able	   to	   raise	   additional	   funds	   from	   existing	   investors.	   Apart	   from	   the	  
financial	   benefit,	   the	   expertise	   and	   input	   from	   TSB	   officials	   were	   seen	   to	   be	   invaluable.	  




Interviewees	   were	   of	   the	   view	   that	   the	   Pharmaceutical	   Price	   Regulation	   Scheme	   (PPRS),	  
negotiated	   between	   the	   industry	   and	   government	   at	   five	   yearly	   intervals,	   had	   in	   general	  
effectively	  supported	  investment	  and	  innovation	  in	  the	  UK	  sector.	  It	  was	  noted	  how	  express	  
account	  was	   taken	   of	   expenditure	   on	   R&D	   and	   other	   items	   in	   deciding	   on	   the	   permitted	  
return	   on	   capital	   for	   individual	   firms.	   The	   2012	   renegotiation	   of	   the	   PPRS	   nevertheless	  
attracted	  some	  criticism	  as	  it	  introduced	  a	  two-­‐year	  freeze	  on	  branded	  drug	  expenditure	  in	  
the	  NHS.	  	  
	  
In	   contrast,	   the	  manner	   in	  which	   the	  government	   sponsored	  National	   Institute	   for	  Clinical	  
Excellence	  (NICE)	  undertook	  health	  technology	  assessments	  of	  new	  drugs	  for	  the	  NHS,	  was	  
seen	  as	  a	  substantial	   impediment	  to	  the	  introduction	  of	  new	  drugs	  in	  the	  UK.	  Interviewees	  
at	  P1	  and	  P2	  noted	  how	  considerations	  of	  economics	  and	  cost	  effectiveness	  dominated	  over	  
other	  social	  benefits	  in	  determining	  whether	  a	  drug	  should	  be	  approved	  for	  use	  in	  the	  NHS.	  
A	  consequence	  of	  this	  was	  low	  adoption	  of	  new	  drugs	  in	  the	  NHS	  compared	  to	  countries	  in	  
Europe	  and	  elsewhere.	  	  
	  
This	   was	   a	   particular	   issue	   for	   drugs	   targeting	   small	   groups	   of	   people	   as	   the	   statistical	  
models	   adopted	   by	  NICE	  made	   it	   extremely	   difficult	   to	   demonstrate	   cost	   effectiveness.	   In	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addition,	   the	   focus	   on	   cost	   and	   economic	   considerations	   was	   identified	   as	   inhibiting	   the	  
adoption	  of	  effective	  but	  expensive	  end-­‐of-­‐life	  cancer	  drugs.	  It	  was	  noted	  that	  in	  France	  and	  
other	   European	   countries	   medical	   or	   social	   benefits	   were	   prioritized	   and	   considered	  
separately	  to	  cost,	  thereby	  promoting	  take-­‐up	  of	  such	  drugs.	  	  
	  
Finally,	   interviewees	  at	  P1	  and	  P4	  highlighted	  the	  problematic	  nature	  of	  conducting	  clinical	  
trials	  within	  the	  NHS.	  The	  process	   for	   later	  stage	  trials	  was	  so	  costly	  and	  bureaucratic	   that	  
both	   organisations	   were	   now	   undertaking	   these	   outside	   of	   the	   UK.	   A	   manager	   at	   P1	  
explained	  how	  the	  devolved	  and	  autonomous	  nature	  of	  decision-­‐making	  within	  the	  NHS	  had	  
been	  highly	  problematic	  in	  this	  regard,	  with	  enormous	  variety	  in	  the	  policies	  and	  practices	  of	  
individual	   trusts.	   This	   interviewee	   did	   however	   note	   that	   steps	   were	   being	   taken	   to	  
streamline	   and	  harmonise	   the	  process	   for	   conducting	   clinical	   trials,	   as	   outlined	   in	   table	   2.	  
Combined	  these	  weaknesses	  created	  sizable	  disincentives	  for	  drug	  development	  activities	  to	  
be	  located	  in	  the	  UK,	  with	  significant	  existing	  investment	  being	  lost	  as	  a	  consequence.	  	  
	  
Financial	  Incentives	  &	  Government	  Approach	  
While	   the	   government’s	   introduction	   of	   R	   &	   D	   tax	   credits	   was	   viewed	   as	   valuable	   and	  
protected	   current	   investments,	   the	   fiscal	   environment	   and	   financial	   incentives	   in	   the	   UK	  
were	   identified	  as	  comparing	  unfavourably	  with	   those	  elsewhere.	   Interviewees	  noted	  how	  
countries	  such	  as	  Ireland	  and	  Singapore	  had	  very	  low	  rates	  of	  corporation	  tax,	  which	  meant	  
they	  were	  more	  attractive	  than	  the	  UK	  as	  locations	  for	  new	  investment.	  Interviewees	  at	  P1	  
and	   P3	   explained	   how	   new	   manufacturing	   facilities	   had	   been	   placed	   in	   these	   countries	  
instead	   of	   the	   UK	   in	   order	   to	   avail	   of	   the	   more	   favourable	   financial	   incentives.	  
Manufacturing	  in	  the	  UK	  was	  therefore	  contracting	  while	  it	  had	  grown	  elsewhere.	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Alongside	   the	   incentives,	   the	   approach	   of	   government	   and	   development	   agencies	   was	   a	  
significant	  influence	  on	  investment	  decisions.	  According	  to	  a	  senior	  manager	  at	  P3,	  Irish	  and	  
Singaporean	   development	   agencies	  were	   ‘very,	   very	   proactive’,	   going	   out	   of	   their	   way	   to	  
facilitate	  inward	  investment.	  In	  contrast,	  the	  UK	  government	  was	  seen	  to	  be	  ‘pretty	  passive	  
towards	  the	  pharmaceutical	  industry.’	  	  
	  
While	   the	   industrial	   policy	   context	   was	   therefore	   seen	   to	   be	   insufficiently	   effective	   in	  
incentivizing	   investment	   and	   innovation,	   the	   situation	  was	   dynamic,	  with	   the	   government	  
attempting	  to	  address	  the	  issues	  raised	  through	  the	  Office	  for	  Life	  Sciences	  and	  subsequent	  
Strategy	  for	  UK	  Life	  Sciences.	  As	  outlined	  in	  table	  2,	  the	  Conservative-­‐Liberal	  government	  has	  
progressively	  reduced	  corporation	  tax,	  with	  a	  ‘patent	  box’	  system	  also	  introduced	  aimed	  at	  
incentivizing	   innovation	   in	   the	   UK.	   Notably,	   P3	   announced	   a	   large	   investment	   in	   a	   new	  




In	  addition	  to	  weaknesses	  in	  discrete	  areas	  interviewees	  highlighted	  a	  lack	  of	  coordination	  in	  
policy	  and	  approaches	  towards	  the	  sector.	  The	  Office	  for	  Life	  Sciences	  initiative	  was	  seen	  to	  
reflect	   a	   change	   towards	   a	   more	   strategic,	   integrated	   approach,	   with	   the	   subsequent	  
Strategy	   for	   Life	  Sciences	  and	  various	   supportive	  Budget	  measures	   illustrating	  a	   continued	  
trend	   in	   this	   regard.	   Nevertheless	   government	   policy	   towards	   the	   sector	   continues	   to	   be	  
characterized	   by	   a	   lack	   coordination	   and	   consistency	   in	   certain	   respects,	   for	   example	  
between	   industrial	   policy	   objectives	   and	   expenditure	   controls	   within	   the	   NHS.	   Next	   we	  





Levels	   of	   employment	   at	   the	   large	  MNCs	   P1,	   P2,	   P3	   and	   P4	   have	   fallen	   significantly	   over	  
recent	  years.	  All	  have	  implemented	  redundancy	  programmes	  across	  their	  R	  &	  D	  workforces.	  
This	  was	  particularly	  marked	  at	  P1	  and	  P4	  with	  flagship	  research	  centres	  closed	  and	  around	  
2000	   R	   &	   D	   jobs	   lost	   at	   each	   firm.	   At	   the	   same	   time	   however	   both	   announced	   sizable	  
investments	  in	  R	  &	  D	  facilities	  and	  personnel	  in	  a	  UK	  region	  renowned	  for	  its	  strength	  in	  the	  
biomedical	  field.	  	  
	  
These	   reductions	   in	   employment	   are	   seen	   to	   be	   primarily	   due	   to	   internal	   company	   and	  
industry	  factors,	  namely	  the	  increase	  in	  cost	  of	  drug	  development	  alongside	  the	  reduction	  in	  
throughput	  of	  successful	  new	  drugs,	  giving	  rise	  to	  an	  urgent	  need	  to	  reduce	  costs	  and	  focus	  
R&D	  efforts.	  A	  notable	  additional	  well	  established	  practice	  was	  the	  outsourcing	  of	  activities	  
such	   as	   early-­‐stage	   molecule	   screening	   to	   contract	   research	   organisations	   in	   lower	   cost	  
countries	  as	  well	  as	  the	  UK.	  	  
	  
The	  decisions	  to	  undertake	  the	  new	  investments	  mentioned	  were	  more	  obviously	  due	  to	  the	  
UK	  policy	   context,	  with	   the	   strong	  biomedical	   capacities	  highlighted	  as	   key.	  A	  more	  direct	  
effect	  of	  the	  policy	  context	  was	  also	  apparent	  in	  relation	  to	  clinical	  trials	  at	  P1,	  where	  a	  small	  
department	   had	   been	   closed	   with	   the	   loss	   of	   a	   number	   of	   jobs	   due	   to	   the	   difficulties	  
experienced	   in	   carrying	  out	   trials	   in	   the	  UK.	   In	   contrast,	   a	  policy	  manager	   at	  P2	  explained	  
how	   a	   new	   investment	   in	   the	   neuroscience	   area	   underpinning	   130	   research	   jobs	   was	  
attributable	  to	  the	  expertise	  of	  UK	  research	  institutions	  in	  this	  field.	  	  
	  
P1,	  P2	  and	  P3	  had	  also	  experienced	  large	  reductions	  in	  their	  manufacturing	  workforces.	  P1	  
and	   P2	   had	   recently	   announced	   over	   2,000	   manufacturing	   redundancies	   between	   them,	  
with	   the	   closure	  of	   a	  number	  of	   factories.	   The	   impact	  of	   the	   industrial	   policy	   context	  was	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also	  more	   prominent	   here,	  with	   new	  manufacturing	   investments	   being	  made	   in	   countries	  
such	   as	   Singapore	   and	   Ireland	   instead	   of	   the	   UK	   due	   to	   the	   more	   favourable	   financial	  
incentives	  offered	  by	  the	  former.	  Notably	  however,	  P3’s	  announcement	  of	  new	  investments	  
in	  R	  &	  D,	  biopharmaceuticals	  and	  manufacturing	  in	  the	  UK	  in	  response	  to	  the	  introduction	  of	  
the	  ‘patent	  box’	  was	  expected	  to	  create	  1000	  new	  jobs.	  	  
	  
The	   lightly	   regulated	   and	   flexible	   nature	   of	   the	  UK	   labour	  market	   greatly	   facilitated	   these	  
various	   reductions	   in	   R	   &	   D	   and	   manufacturing	   employment.	   P1	   and	   P4	   announced	   the	  
closure	  of	   their	  R	  &	  D	   facilities	   suddenly	  without	  prior	   consultation	  with	  workers	  or	   trade	  
unions.	   Trade	   union	   officials	   were	   highly	   critical	   of	   this,	   noting	   that	   such	   sudden	  
announcements	  of	  job	  losses	  would	  not	  be	  possible	  in	  France	  or	  Germany	  due	  to	  the	  stricter	  
regulations	   there	   concerning	   employee	   consultation	   and	   the	   implementation	   of	  
redundancies.	   They	   highlighted	   how	   previous	   substantial	   investments	   in	   the	   affected	  
workforces	   and	   locations	   would	   now	   be	  wasted,	   leading	   to	   serious	   issues	   regarding	   skills	  
utilisation.	   They	   argued	   that	   the	   UK	   government	   should	   be	   much	   more	   hands-­‐on	   and	  
proactive	  in	  ensuring	  that	  the	  skills	  of	  pharmaceutical	  workers	  in	  the	  UK	  are	  used,	  instead	  of	  
industry	   employees	   being	   so	   subject	   to	  market	   fluctuations	   and	   business	   decisions	  within	  
individual	  firms.	  	  	  
	  
Employment	  at	   the	   small	   start-­‐up	   company	  P5	  had	  grown	   somewhat	   since	   its	   foundation,	  
however	  it	  still	  only	  employed	  twelve	  people	  in	  total.	  Prospects	  for	  employment	  growth	  at	  
this	   and	  other	   biopharmaceutical	   start-­‐ups	  were	  not	   strong	  due	   to	   the	   limited	  budgets	   of	  
these	  firms	  arising	  from	  the	  difficulties	  in	  accessing	  financial	  support	  (Ernst	  and	  Young	  2010).	  
A	  senior	  manager	  at	  P5	  explained	  how	  financial	  controls	  in	  that	  company	  were	  so	  tight	  that	  
they	  ‘count	  the	  paper	  clips.’	  	  Next	  we	  examine	  wider	  evidence	  on	  industry	  performance	  and	  
employment	  drawing	  on	  secondary	  data.	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Wider	  Evidence	  
An	  official	  government	  report	  based	  on	  a	  comprehensive	  industry	  database	  outlines	  that	  in	  
2014	  the	  UK	  pharmaceutical	  sector	  employed	  70,000	  people,	  including	  57,000	  in	  companies	  
discovering,	   developing	   and	   marketing	   medicines,	   and	   had	   a	   turnover	   of	   £32	   billion.	  
Alongside	  this	  the	  medical	  biotechnology	  sector	  employed	  23,000	  people	  with	  a	  turnover	  of	  
generated	  turnover	  of	  £5	  billion.	  Combined	  this	  gives	  a	  sector	  employing	  93,000	  in	  total	  with	  
a	  turnover	  of	  £37	  billion	  (HM	  Government	  2015a).	  	  	  
	  
Employment	   trends	   in	   the	   broader	   chemicals	   and	   pharmaceutical	   sector	   have	   mirrored	  
those	   in	  the	  manufacturing	  sector	  as	  a	  whole,	  with	  a	  61%	  reduction	   in	  numbers	  employed	  
between	  1979	  and	  2013	   (Hardie	   and	  Banks	   2014).	  As	  outlined	   in	   figure	  1,	   despite	   various	  
fluctuations	  in	  manufacturing	  and	  R&D	  employment,	  overall	  numbers	  in	  the	  pharmaceutical	  
sector	   remained	   quite	   stable	   between	   1995	   and	   2012.	   This	   does	   not	   however	   take	   into	  
account	  the	  substantial	  job	  losses	  in	  2013.	  	  	  
	  
	   <<Insert	  figure	  1	  about	  here	  >>	  
	  
Eurostat	  data	  enables	  some	  comparative	  assessment	  of	  employment	   in	  UK	  pharmaceutical	  
manufacturing.	   According	   to	   this	   there	   were	   50,000	   people	   employed	   in	   pharmaceutical	  
manufacturing	  in	  the	  UK	  in	  2012,	  compared	  with	  76,000	  in	  France	  and	  122,000	  in	  Germany	  
(Eurostat	  2015).	  	  
	  	  
Wage	  and	  qualification	  levels	  in	  the	  UK	  sector	  are	  comparatively	  high.	  The	  Annual	  Survey	  of	  
Hours	  and	  Earnings	  show	  that	  in	  2013	  the	  median	  gross	  hourly	  wage	  in	  pharmaceuticals	  was	  
£17.63,	   compared	   with	   £12.58	   for	   manufacturing	   as	   a	   whole	   and	   £11.59	   for	   all	   UK	  
employees.	   Cogent	   (2010:	   11)	   estimates	   that	   58%	   of	   the	   pharmaceuticals	   workforce	   is	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educated	  to	  National	  Vocational	  Qualification	   level	  4	  or	  above	  (i.e.	  degree	   level	  or	  above),	  
compared	  with	  under	  32%	  for	  the	  labour	  force	  as	  a	  whole.	  
	  
Gross	  value	  added	  (GVA)	  in	  the	  sector	  fell	  quite	  sharply	  in	  2010	  and	  has	  been	  flat	  since	  then.	  
It	  nevertheless	  remains	  comparatively	  high,	  with	  GVA	  per	  person	  employed	  being	  £135,000	  
in	  2012	  compared	  to	  £60,000	  for	  manufacturing	  as	  a	  whole	   (ONS	  2015b).	  Pharmaceuticals	  
has	  been	  the	   largest	  contributor	   to	   the	  total	  expenditure	  on	  business	  R&D	   in	   the	  UK	  since	  
1988	  (ONS	  2014).	  In	  2013,	  the	  industry	  invested	  £4.1	  billion,	  accounting	  for	  22%	  of	  the	  total.	  	  
The	  sector	  had	  an	  average	  annual	  trade	  balance	  of	  +£4.2bn	  between	  2005	  and	  2014	  (HMRC	  
2015).	  	  
	  
The	  flexible	  and	  lightly	  regulated	  nature	  of	  the	  UK	  labour	  market	  regulation	  was	  highlighted	  
above	   as	   a	   perceived	   weakness	   of	   the	   institutional	   context,	   by	   enabling	   firms	   and	   large	  
MNCs	   in	   particular	   to	   cut	   jobs	   with	   little	   or	   no	   consultation.	   At	   the	   same	   time	   the	   UK	  
continues	  to	  attracts	  a	  large	  amount	  of	  foreign	  direct	  investment	  in	  the	  life	  sciences	  sector,	  
with	   fifty	   investment	   projects	   announced	   in	   2013.	   This	   was	   significantly	   higher	   than	   in	  
France,	  for	  example	  (HM	  Government	  2015b:15).	  The	  UK	  has	  by	  far	  the	  biggest	  pipeline	  of	  
new	  products	   in	   Europe,	   although	   the	   take-­‐up	  of	   new	  medicines	  by	   the	  healthcare	   sector	  
remains	  very	  low	  (Ernst	  and	  Young	  2015:	  95;	  HM	  Government	  2015b:	  35).	  	  	  
	  
Discussion	  and	  Conclusion	  
While	  the	  adoption	  of	  a	  strategic	  industrial	  policy	  has	  been	  identified	  as	  a	  possible	  lever	  to	  
shift	  the	  UK	  economy	  to	  a	  high	  wage,	  high	  skill	  trajectory,	  there	  has	  been	  a	   lack	  of	  related	  
research	  (Lloyd	  and	  Payne	  2002).	  This	  paper	  has	  attempted	  to	  address	  this	  gap	  by	  examining	  
the	   impact	   of	   industrial	   policy	   on	   performance	   and	   employment	   in	   pharmaceuticals,	   an	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important	   sector	   in	   which	   government	   policy	   and	   support	   has	   historically	   played	   a	  
comparatively	  central	  role.	  
	  
The	   paper	   began	   by	   defining	   industrial	   policy,	   outlining	   associated	   measures	   and	  
instruments	   identified	   in	   the	   literature	   and	   considering	   its	   impact	   on	   employment.	   A	  
theoretical	  framework	  and	  analytical	  tools	  were	  outlined	  which	  future	  research	  can	  draw	  on	  
(Hannon	  et	   al	   2011;	  Hannon	  2014).	   The	   challenges	   in	  establishing	   the	   impact	  of	   industrial	  
policy	  were	  highlighted	  (Greene	  et	  al	  2008).	  While	  challenges	  remain,	  the	  research	  methods	  
adopted	  comprising	  interviews	  with	  policymakers,	  qualitative	  case	  research	  at	  firm	  level	  and	  
a	   wide	   range	   of	   secondary	   data,	   aided	   an	   overall	   assessment	   of	   the	   impact	   of	   industrial	  
policy	  on	  performance	  and	  employment	  in	  the	  UK	  pharmaceutical	  sector.	  	  
	  
The	  findings	  demonstrate	  how	  the	  policy	  and	   institutional	  context	   in	  the	  UK	  facilitated	  the	  
development	  of	  a	  vibrant	  pharmaceutical	  industry.	  Over	  the	  last	  10-­‐15	  years	  state	  industrial	  
policy	  towards	  the	  sector	  has	  become	  more	  strategic	  and	  active.	  Pharmaceuticals	  has	  been	  
identified	  as	  a	  key	  knowledge-­‐intensive	  sector	  and	  the	  government	  has	   introduced	  various	  
measures	  and	  initiatives	  and	  established	  structures	  to	  support	  it.	  	  
	  
The	  case	  studies	  highlighted	  the	  importance	  of	  UK	  industrial	  policy	  for	  pharmaceutical	  firms,	  
with	   the	   industrial	   policy	  measures	   from	   the	   literature	   identified	   as	   significant	   for	   the	  UK	  
sector.	  Various	  aspects	  or	  elements	  as	  well	  as	  the	  nature	  and	  extent	  of	  coordination	  across	  
the	  same	  had	  tangible	  consequences	  for	  firm	  strategies	  and	  consequently	  employment.	  The	  
industrial	  policy	  framework	  was	  seen	  by	  industry	  officials	  and	  managers	  as	  becoming	  more	  
positive	  and	  favourable	  over	  time.	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While	  weaknesses	  and	  challenges	  are	  apparent	  overall	  we	  can	  conclude	  that	  the	   industrial	  
policy	   context	  has	   supported	   the	   competitive	  position	   and	  performance	  of	   the	   sector	   and	  
consequently	  employment.	  Although	  total	  manufacturing	  employment	  is	  substantially	  lower	  
than	   in	   France	   or	  Germany,	   combined	   pharmaceutical	   and	   biomedical	   activities	   in	   the	  UK	  
constitute	   a	   sizable	   and	   high	   value	   sector	   characterised	   by	   comparatively	   strong	  
performance	  and	  jobs	  that	  are	  highly	  skilled	  and	  paid.	  	  
	  
The	   research	   makes	   an	   important	   contribution	   to	   debates	   on	   the	   political	   economy	   of	  
employment	  and	  skills	  in	  the	  UK.	  It	  demonstrates	  the	  potential	  of	  an	  active	  industrial	  policy	  
to	  support	  growth	  and	  competitiveness	  and	  consequently	  underpin	  high	  quality	  jobs	  (Lloyd	  
and	  Payne	  2002;	  Brown	  et	  al	  2015).	  At	  the	  same	  time	  the	  pharmaceutical	  case	  highlights	  the	  
importance	   of	   assessment	   and	   possible	   adjustment	   of	   policy	   and	   institutions	   in	   related	  
spheres	  such	  as	  labour	  market	  regulation	  (Hannon	  et	  al	  2011).	  
	  
	  
While	  pharmaceuticals	  could	  be	  seen	  as	  something	  of	  a	  special	  case	  given	  the	  centrality	  of	  
public	  policy	  and	  institutions	  to	  it,	  there	  is	  evidence	  of	  some	  similar	  patterns	  of	  substantial	  
support	  and	  collaboration	  in	  other	  sectors,	  for	  example	  automotive	  (BIS/Automotive	  Council	  
2013).	  This	  arguably	  supports	  and	  calls	  for	  more	  nuanced	  analysis	  of	  the	  nature	  and	  role	  of	  
industrial	  policy	  in	  the	  UK	  and	  points	  to	  the	  value	  of	  detailed	  sectoral	  research	  as	  conducted	  
here.	  More	  broadly,	  the	  research	  emphasises	  the	  general	  role	  and	  importance	  of	  industrial	  
policy	   in	   supporting	   high-­‐wage,	   high-­‐skill	   employment,	   even	   in	   so-­‐called	   ‘liberal	   market	  
economy’	  contexts	  (Bloch	  2008;	  Hannon	  et	  al	  2011;	  Hannon	  2014).	  	  
	  
From	   a	   policy	   perspective,	   the	   importance	   of	   proactive,	   committed	   and	   consistent	  
government	   management	   and	   support	   to	   the	   success	   of	   industrial	   policy	   in	   the	  
25	  	  
contemporary	  economy	  must	  be	  emphasised.	  That	  the	  general	  role	  of	   industrial	  policy	  has	  
reportedly	  been	  questioned	  and	  downplayed	  by	  the	  Conservative	  administration	  elected	  in	  
May	   2015	   is	   therefore	   a	   cause	   for	   concern	   (Financial	   Times,	   June	   8th	   2015).	   	   While	  
unsurprising	  given	  the	  political	  and	  contested	  nature	  of	  industrial	  policy	  in	  the	  UK,	  the	  lack	  
of	   impetus	   and	   focus	   that	   may	   result	   could	   be	   detrimental	   to	   industry	   performance	   and	  
employment.	  
	  
Finally,	  for	  sectors	  not	  benefitting	  from	  industrial	  policy	  support	  there	  will	  continue	  to	  be	  an	  
onus	   on	   employment	   scholars	   to	   research	   and	   argue	   for	   changes	   in	   policy	   and	   regulatory	  
frameworks	  that	  would	  promote	  desirable	  employment	  and	  skills	  outcomes	  (Grimshaw	  et	  al	  
2008).	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Table	  1:	  Ten	  Key	  Industrial	  Policy	  Activities	  &	  Associated	  Measures	  
Activity	   Summary/Examples	  
Provision	  of	  direct	  financial	  support	  to	  
R	   &	   D	   intensive	   or	   innovative	  
industries	  
Grants,	  loans	  or	  subsidies	  targeted	  to	  specific	  firms,	  
sectors	   or	   technologies.	   Assumption	   of	   ownership	  
stake	  in	  early-­‐stage	  technology	  firms	  
Creation	   of	   financial	   incentives	   to	  
invest	  &	  innovate	  
Adjustment	   of	   tax	   rates;	   introduction	   of	   R&D	   tax	  
credits	  
	  
State	   funding	   of	   public	   research	   &	  
development	  
Strategic	   investment	   by	   government	   in	   public	  
institutions	   in	   basic	   or	   applied	   research	   in	   high-­‐
value	  or	  emerging	  areas	  
Developing	  clusters	  &	  networks	   Creating	   &	   strengthening	   links	   between	   firms,	  
universities	   &	   other	   institutions	   in	   the	   same	  
industry	  or	  region	  
Strengthening	  capabilities	   Investing	  in	  general	  &	  industry-­‐specific	  education	  &	  
training;	  public	  investment	  in	  science	  &	  technology	  
infrastructure,	  e.g.	  research	  institutes	  
Attraction	  of	  inward	  investment	  
	  
Attracting	  multinational	   investment,	   particularly	   in	  
high	  value	  sectors	  
	  
Regulation	   of	   product	   or	   service	  
standards	  
	  
Setting	   high	   quality	   or	   safety	   standards,	  
underpinning	   comparative	   advantage	   for	  
indigenous	   firms;	  Use	  of	  government	  procurement	  
to	  raise	  standards	  
Stimulation	   of	   product	   market	  
competition	  
	  
Deregulation	   &	   opening	   industries	   to	   competition	  
to	  promote	  dynamism	  &	  creativity	  
Business	  advice	  &	  brokering	   Helping	   firms	   develop	   their	   strategies,	   adopt	   best	  
management	   practice	   and	   make	   business	  
connections	  
Facilitation	   E.g.	   creating	   supportive	   regulatory	   frameworks	   for	  
new	   products	   or	   ensuring	   suitable	   physical	  
infrastructure	  
	  
	   	  
33	  	  
Table	  2:	  Overview	  of	  the	  case	  study	  firms	  
Company	  	   P1	   P2	   P3	   P4	   P5	  
Ownership	   MNC	   MNC	   MNC	   MNC	   Indigenous/	  
private	  
No.	   of	  
Employees	  
>2000	   >1000	   >2000	   >2000	   >10	  





















Developing	   a	  
vaccine	   to	  
treat	   liver	  
complaints	  





20	   8	   14	   5	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Table	  3:	  Recent	  State	  Initiatives	  in	  Support	  of	  Pharmaceuticals	  	  
Initiative	   Summary	  
Biomedical	   Catalyst	  
Programme	  
• £180	  million	  programme	  operated	  by	  the	  Medical	  Research	  
Council	  &	  Technology	  Strategy	  Board	  (now	  Innovate	  UK)	  
• Support	   for	   SMEs	   and	   academic	   partners	   to	   undertake	  
collaborative	  R	  &	  D	  projects	  	  
• Grants	   for	  Feasibility,	   ‘Confidence	   in	  Concept’	  &	   later	   stage	  
projects	  
Stratified	   Medicine	  
Innovation	   Platform	   &	  
Regenerative	   Medicine	  
Programme	  	  
• Led	  by	  the	  Technology	  Strategy	  Board	  
• Investment	  of	  over	  £60	  million	  &	  £21.5	  million	   respectively	  
for	  collaborative	  R	  &	  D	  in	  these	  areas	  
• £50	   million	   investment	   in	   Precision	   Medicine	   Catapult	  
(innovation	  centre)	  
Promotion	   of	   cell	   therapy	  
research	   &	   biologic	  
manufacture	  
• Cell	   Therapy	   Catapult	   established	   to	   promote	   commercial	  
translation	   of	   cell	   therapy	   research;	  works	  with	   companies	  
on	  specific	  projects.	  £55	  million	  Cell	  Therapy	  Manufacturing	  
Centre	  announced	  budget	  2014	  	  
• £38	   million	   National	   Biologics	   Manufacturing	   Centre:	   large	  
scale	  open	  access	  facility	  to	  support	  companies	  develop	  new	  
process	   technologies	   for	   the	   manufacture	   of	   biologic	  
medicines	  (e.g.	  antibodies)	  
Translational	   Research	  
Partnerships	  
• Involve	   industry,	   the	   NHS	  &	   academic	   researchers	  working	  
together	   on	   early	   stage	   clinical	   development	   of	   drugs	   in	  
critical	  areas	  (e.g.	  inflammatory	  respiratory	  diseases)	  
• Draw	   on	   the	   government’s	   £775	   million	   investment	   in	  
Biomedical	  Research	  Centres	  and	  Units	  
Financial	  incentives	   • Progressive	  reduction	  of	  corporation	  tax	  from	  26%	  to	  20%	  	  
• Reduced	   10%	   tax	   on	   profits	   from	   innovations	   developed	  &	  
commercialized	   in	   the	   UK	   from	   April	   2013	   (‘patent	   box’	  
system)	  
• Adjustment	   of	   rules	   on	   R	   &	   D	   tax	   credits	   and	   investment	  
allowances	  to	  promote	  investment	  in	  SMEs	  
Reform	   of	   Institutions	   &	  
Processes	  
• Health	   Research	   Authority	   created	   December	   2011	   to	  
establish	   unified	   approval	   process	   &	   operational	   standards	  
for	  clinical	  trials	  	  
• Office	  for	  Clinical	  Research	  Infrastructure	  set	  up	  to	  facilitate	  
linkages	  between	  industry,	  universities	  and	  the	  NHS	  
Promoting	   Foreign	   Direct	  
Investment	  
• Agency	  UK	   Trade	  &	   Investment	   has	   developed	   a	   dedicated	  
life	  sciences	  marketing	  &	  promotion	  campaign	  
• Life	   Sciences	   Investment	   Organisation	   established	   to	  
promote	  inward	  investment	  
	  
Sources:	  interviews,	  documentation	  &	  relevant	  websites	  
